These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 10408697)

  • 21. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
    Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
    Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
    Riedel F; Götte K; Li M; Hörmann K; Grandis JR
    Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro chemosensitivity testing of squamous cell carcinoma of the head and neck. A preliminary report.
    Elprana D; Schwachöfer J; Kuijpers W; van den Broek P; Wagener DJ
    Acta Otolaryngol; 1987; 103(5-6):529-36. PubMed ID: 2441566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin.
    Cemazar M; Miklavcic D; Scancar J; Dolzan V; Golouh R; Sersa G
    Br J Cancer; 1999 Mar; 79(9-10):1386-91. PubMed ID: 10188880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
    Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.
    Los G; Benbatoul K; Gately DP; Barton R; Christen R; Robbins KT; Vicario D; Kirmani S; Orloff LA; Weisman R; Howell SB
    Clin Cancer Res; 1999 Jul; 5(7):1610-8. PubMed ID: 10430059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma.
    Nakashima T; Yasumatsu R; Kuratomi Y; Masuda M; Kuwano T; Toh S; Umezaki T; Cataltepe S; Silverman GA; Komune S
    Head Neck; 2006 Jan; 28(1):24-30. PubMed ID: 16155915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
    Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
    Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
    Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo interaction of cis-platinum and fosfomycin on squamous cell carcinoma.
    Tandy JR; Tandy RD; Farris P; Truelson JM
    Laryngoscope; 2000 Jul; 110(7):1222-4. PubMed ID: 10892700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.
    McDonald ES; Randon KR; Knight A; Windebank AJ
    Neurobiol Dis; 2005 Mar; 18(2):305-13. PubMed ID: 15686959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
    van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
    Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38.
    Thomas SM; Zeng Q; Epperly MW; Gooding WE; Pastan I; Wang QC; Greenberger J; Grandis JR
    Clin Cancer Res; 2004 Oct; 10(20):7079-87. PubMed ID: 15501988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.